Synthetic Biologist | Biotech Entrepreneur | MIT Professor
- Tweets 338
- Following 783
- Followers 4,629
- Likes 139
RT @SentiBio: Dr. Kanya Rajangam, Chief Medical Officer, emphasized that the encouraging SENTI-202 data support advancement into pivotal st…
3
Thanks to Dr. Farhad Ravandi from @MDAndersonNews for sharing thoughts on the potential for $SNTI's SENTI-202 product to transform the treatment of AML and other cancers. Published by @VJHemOnc vjhemonc.com/video/nvzwt-dus…
4
3
958
Thanks to @GeneOnlineNews for highlighting @SentiBio 's recent SENTI-202 data for R/R AML @ ASH. With 50% ORR, RMAT designation, favorable safety, off-the-shelf delivery, we hope to advance this program quickly into pivotal studies for patients in need
geneonline.com/senti-bio-win…
2
1
3
651
$SNTI recently reported our Logic Gated SENTI-202 cell therapy achieved 50% ORR, 42% CR/CRh, 7.6 month cCR durability in heavily pretreated refractory/refractory AML patients at #ASH25. This is an exciting new treatment modality for R/R AML, a disease with a median OS ~5 months
Dr. Nosha Farhadfar noted that SENTI-202 is demonstrating deep, durable responses and a favorable safety profile in R/R AML, underscoring its potential to selectively target AML cells while preserving healthy ones.
bit.ly/3XFf7ST
$SNTI #AML #ASH2025
5
2
5
1,131
Timothy Lu retweeted
If you missed our CEO, Tim Lu, at the H.C. Wainwright 27th Annual Global Investment Conference, don’t worry — you can watch the full presentation now!
🎥 Replay available here: bit.ly/4mK46dE
$SNTI #CellTherapy #AML #CARNK #AcuteMyeloidLeukemia
1
2
5
991
Excited to share updates on Senti Bio’s SENTI-202 program with Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML. Come join us at 830 AM ET webinar! $SNTI investors.sentibio.com/news-…
2
1
9
1,459
Timothy Lu retweeted
Kanya Rajangam, MD, PhD, President and Chief Medical Officer of $SNTI, shares her excitement for the upcoming data presentation from the SENTI-202 trial at the AACR Annual Meeting being held April 25-30, 2025
bit.ly/3QYtOx5
@AACR
291
572
5,522
9,658,005
Timothy Lu retweeted
#MarkYourCalendars: $SNTI leadership will host a conference call and webcast to discuss the new SENTI-202 Phase 1 clinical data being presented at #AACR2025 on Monday, April 28, 2025, at 8:30 AM ET. Access it here: bit.ly/3S668ap
#CellTherapy #CARNK #AML @AACR
4
4
5
2,113
Timothy Lu retweeted
Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025
bit.ly/3QYtOx5
$SNTI #CellTherapy #CARNK @AACR #AACR25
295
516
4,799
11,428,730
Excited to share the latest clinical and preclinical data on our Logic Gated SENTI-202 product at the upcoming AACR meeting!
Kanya Rajangam, MD, PhD, President and Chief Medical Officer of $SNTI, shares her excitement for the upcoming data presentation from the SENTI-202 trial at the AACR Annual Meeting being held April 25-30, 2025
bit.ly/3QYtOx5
@AACR
2
1
785
Very excited to share details on SENTI-202 clinical trial - 2 of 3 pts achieved MRD negative CR in 1st dose level evaluated with a generally well-tolerated preliminary safety profile. Both patients continue to maintain remission (4+ and 3+ months, respectively). $SNTI
Today, we announced positive initial clinical data from the Phase 1 trial of SENTI-202, a potential first-in-class, off-the-shelf #CARNK #celltherapy for R/R hematologic malignancies, including #AML. Learn more on our webcast on Dec. 3 at 7:30am ET: bit.ly/4eUaKtb $SNTI
1
11
2,306
Excited to share the detailed data on SENTI-202 with Dr. Stephen Strickland and Dr. Kanya Rajangam. Join us to learn about how our #genecircuits enhanced CAR-NK therapies have the potential to transform the treatment of cancer through Logic Gating. $SNTI
Join us for a live webcast where Senti management and Dr. Stephen Strickland will discuss the positive initial clinical data from the Phase 1 clinical trial of SENTI-202, a Logic-Gated, selective CD33/FLT3-targeting #CARNK #celltherapy. Access here: bit.ly/4eUaKtb $SNTI
1
1
9
2,188
Timothy Lu retweeted
Join us for a live webcast where Senti management and Dr. Stephen Strickland will discuss the positive initial clinical data from the Phase 1 clinical trial of SENTI-202, a Logic-Gated, selective CD33/FLT3-targeting #CARNK #celltherapy. Access here: bit.ly/4eUaKtb $SNTI
1
2
12
3,867
Congratulations to @SentiBio for its $8M award from California Institute for Regenerative Medicine (CIRM) for its Logic-Gated SENTI-202 clinical trial for relapsed/refractory AML. Thanks so much to CIRM for this support! $SNTI
cirm.ca.gov/about-cirm/newsr…
1
14
1,329
Timothy Lu retweeted
We @abscibio are excited to unveil IgDesign™ @NeurIPSConf and present our work at @workshopmlsb @AI4D3 @genbio_workshop! IgDesign is an antibody inverse folding model that we have experimentally validated in our lab. Read the paper here: biorxiv.org/content/10.1101/… #NeurIPS2023
3
35
131
21,187
Check out how $SNTI's Logic Gates precisely discriminate between cancer cells and healthy cells, allowing us to achieve highly precise cancer therapeutics! #synbio
1
1
10
3,761
Exciting times for @SentiBio as we gain extra fuel to power our Gene Circuit enhanced cell therapies to patients.
Today, we announced that Celadon Partners will acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies. Learn more: bit.ly/3KzwjmH
1
2
24
5,953
Timothy Lu retweeted
Nature research paper: Sub-1.4 cm3 capsule for detecting labile inflammatory biomarkers in situ go.nature.com/44YF29F
8
45
37,915
Really excited to publish this work with Maria Eugenia Inda, Gio Traverso, Rabia Yazicigil, and other colleagues advancing a miniaturized pill with living cells for sense-and-respond in vivo!
Nature research paper: Sub-1.4 cm3 capsule for detecting labile inflammatory biomarkers in situ go.nature.com/44YF29F
10
46
7,582
Congratulations to the @openprotein team and @tbepler1 on this exciting new publication. Opportunities for ML-driven protein design continue to grow!
Excited to announce PoET, our (@timt1630, @tbepler1) retrieval-augmented generative protein language model that achieves state-of-the-art unsupervised variant function prediction performance on #ProteinGym. #MachineLearning #ProteinML 1/9
arxiv.org/abs/2306.06156
1
9
1,886